The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 908 DEVICES INC | COM | 65443P102 | 10,615 | 326,427 | SH | SOLE | 326,427 | 0 | 0 | ||
| ABSCI CORP. | COM | 00091E109 | 672 | 57,804 | SH | SOLE | 57,804 | 0 | 0 | ||
| ACUMEN PHARMACEUTICALS, INC | COM | 00509G209 | 50,778 | 3,417,075 | SH | SOLE | 3,417,075 | 0 | 0 | ||
| CANDEL THERAPEUTICS, INC | COM | 137404109 | 8,799 | 811,737 | SH | SOLE | 811,737 | 0 | 0 | ||
| DICE THERAPEUTICS, INC. | COM | 23345J104 | 103,129 | 3,148,970 | SH | SOLE | 3,148,970 | 0 | 0 | ||
| KARUNA THERAPEUTICS, INC. | COM | 48576A100 | 32,772 | 267,895 | SH | SOLE | 267,895 | 0 | 0 | ||
| REPLIGEN CORP. | COM | 759916109 | 6,515 | 22,544 | SH | SOLE | 22,544 | 0 | 0 | ||
| SPRUCE BIOSCIENCES INC | COM | 85209E109 | 4,730 | 787,007 | SH | SOLE | 787,007 | 0 | 0 | ||
| TARSUS PHARMACEUTICALS INC | COM | 87650L103 | 5,603 | 260,000 | SH | SOLE | 260,000 | 0 | 0 | ||
| TAYSHA GENE THERAPIES INC | COM | 877619106 | 13,497 | 724,873 | SH | SOLE | 724,873 | 0 | 0 | ||
| DOORDASH INC | COM CL A | 25809K105 | 129,812 | 630,217 | SH | SOLE | 630,217 | 0 | 0 | ||
| SNOWFLAKE INC | COM CL A | 833445109 | 95,742 | 316,576 | SH | SOLE | 316,576 | 0 | 0 | ||
| UIPATH INC | COM CL A | 90364P105 | 200,538 | 3,811,779 | SH | SOLE | 3,811,779 | 0 | 0 | ||